(NASDAQ: AVXL) Anavex Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Anavex Life Sciences's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast AVXL's revenue for 2026 to be $23,573,604,551, with the lowest AVXL revenue forecast at $0, and the highest AVXL revenue forecast at $72,800,837,584. On average, 4 Wall Street analysts forecast AVXL's revenue for 2027 to be $11,968,178,933, with the lowest AVXL revenue forecast at $3,554,982,481, and the highest AVXL revenue forecast at $20,830,617,666.
In 2028, AVXL is forecast to generate $29,644,808,422 in revenue, with the lowest revenue forecast at $9,841,693,986 and the highest revenue forecast at $50,488,828,304.